CD19 and mantle cell lymphoma: In another study by Schubert et al., 8 patients (2 adults with r/r ALL, 2 r/r CLL, 2 DLBCL, 1 transformed FL, and 1 mantle cell lymphoma (MCL)) received CD19-targeted CAR-T cells at doses of either 1x106 or 5×106 transduced cells/m2 as part of a dose-escalation protocol targeting up to 20x106 cells/m2.